Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Annals Abbassi Shaheed Hospital and Karachi Medical and Dental College. 2006; 11 (1): 884-890
in English | IMEMR | ID: emr-164653
2.
Experimental & Molecular Medicine ; : 84-87, 2000.
Article in English | WPRIM | ID: wpr-75099

ABSTRACT

The precise mechanism whereby granulocytes proliferate when haematopoietic colony stimulating factors (CSFs) are used in neutropenic cancer patients is poorly understood. The purpose of this study was to investigate whether these cytokines bring about leucocyte proliferation by increasing the levels of multiple forms of dihydrofolate reductase (DHFR). Blood samples were collected from 36 cancer patients (25 males and 11 females) with chemotherapy-induced neutropenia. One sample of blood from each patient was obtained before therapy either with CSF, such as granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) or with placebo, and another one at the time of resolution of neutropenia. Peripheral blood leucocytes in these blood samples were counted, separated and lysed. From lysates, cytoplasmic samples were prepared and analyzed for active DHFR by a methotrexate-binding assay and for total immunoreactive DHFR by an enzyme linked immunosorbent assay. The increase in total leucocyte count (TLC) was most prominent (P < 0.005) in the CSF group and less so (P < 0.05) in the placebo group. The mean +/- SD concentration values of active DHFR before and after stimulation with GM-CSF found were to be 0.34 +/- 0.4 ng/mg protein and 0.99 +/- 0.82 ng/mg protein, respectively, and in the group treated with G-CSF, 0.24 +/- 0.32 ng/mg protein and 1.18 +/- 2.4 ng/mg protein, respectively. This increase in active DHFR after stimulation with CSF was statistically significant (P <0.05). Similarly, concentration values of immunoreactive but nonfunctional form of DHFR (IRE) were 110 +/- 97 ng/mg protein and 605 +/- 475 ng/mg protein before and after stimulation with GM-CSF, and 115 +/- 165 ng/mg protein and 1,054 +/- 1,095 ng/ mg protein before and after stimulation with G-CSF. This increase in concentration of IRE after stimulation with GM-CSF or G-CSF was statistically significant (P < 0.005). In the control group, there was an increase in the concentration of both active DHFR and IRE after treatment with placebo. However, this was not statistically significant. Resolution of neutropenia was quicker in the groups treated with CSF compared to the control group. Results of this study indicate that colony stimulating factors (G-CSF and GM-CSF) induce white cell proliferation by increasing the levels of multiple forms of DHFR.


Subject(s)
Adult , Child , Female , Humans , Male , Adolescent , Cell Division/drug effects , Granulocyte Colony-Stimulating Factor/therapeutic use , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte Colony-Stimulating Factor/adverse effects , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects , Isoenzymes/metabolism , Isoenzymes/biosynthesis , Leukocyte Count , Leukocytes/pathology , Leukocytes/enzymology , Leukocytes/drug effects , Middle Aged , Neoplasms/enzymology , Neoplasms/drug therapy , Neoplasms/blood , Neutropenia/metabolism , Neutropenia , Neutropenia/blood , Tetrahydrofolate Dehydrogenase/metabolism , Tetrahydrofolate Dehydrogenase/biosynthesis
3.
JPMA-Journal of Pakistan Medical Association. 1999; 49 (12): 294-297
in English | IMEMR | ID: emr-51302

ABSTRACT

HER 2/new oncogene is an important prognostic marker in Breast Cancer and has implications in therapy planning. To describe the clinical features of HER 2/new positive and negative Breast Cancer in the Pakistani patient population and note clinical differences between the two groups if any. A retrospective analysis of Breast Cancer cases at the Aga Khan University, Hospital. Immunochemical staining on formation fixed paraffin embedded tissue using oxidase antiperoxidase method. A total of 152 Breast cancer tissue samples were tested for HER-2/neu gene presence. Of these 43 [39%] samples tested positive and 109 [61%] tested negative. A comparison of the two groups revealed that only a few factors tested for either significance or borderline statistical significance between the two groups. These factors included the estrogen receptor status and the number of lymph nodes involved in the axilla. The progesterone receptor status was of borderline significance. Given the large number of factors tested it appears that there is no consistent defining feature which helps to separate HER-2/neu positive versus HER-2/neu negative cases with Breast Cancer


Subject(s)
Humans , Female , Receptor, ErbB-2 , Proto-Oncogenes , Genes, erbB-2 , Immunohistochemistry
4.
JPMA-Journal of Pakistan Medical Association. 1997; 47 (9): 236-238
in English | IMEMR | ID: emr-45221
5.
Pakistan Journal of Otolaryngology-Head and Neck Surgery. 1993; 9 (4): 200-202
in English | IMEMR | ID: emr-119231

ABSTRACT

Intractable pharyngeal haemorrhage as a result of trauma or neoplastic erosion of a blood vessel in the neck is sometimes difficult to control. Considering the fact that the management has to be tailored according to the prevailing circumstances, surgical airway is established by tracheostomy using midline incision and then pharynx is packed with roll gauze using McIntosh Laryngoscope and McGill Forceps. The pack is left in the pharynx until proximal or distal control has been achieved. Decannulation is done after physiological, airways are normal. This method has been successfully used in two patients


Subject(s)
Humans , Male , Pharyngeal Diseases/therapy
SELECTION OF CITATIONS
SEARCH DETAIL